

CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor for use in treatment or prevention of opioid-induced constipation.
2. The pharmaceutical composition for use according to claim 1, wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof.
3. The pharmaceutical composition for use according to claim 1, wherein the DGAT1 inhibitor is 3-(4-(6-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-1*H*-benzo[*d*]imidazol-2-yl)-3,5-dimethylphenyl)-2,2-dimethylpropanoic acid (compound 9) or a pharmaceutically acceptable salt or ester thereof.
4. The pharmaceutical composition for use according to claim 1, wherein the DGAT1 inhibitor is an antibody.
5. A diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor for use in treatment or prevention of gastrointestinal dysfunction.
6. The DGAT1 inhibitor for use according to claim 5, wherein the gastrointestinal dysfunction is constipation.
7. The DGAT1 inhibitor for use according to claim 6, wherein the constipation is opioid-induced constipation.
8. The DGAT1 inhibitor for use according to any one of claims 5 to 7, wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof.
9. The DGAT1 inhibitor for use according to any one of claims 5 to 7, wherein the DGAT1 inhibitor is 3-(4-(6-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-1*H*-benzo[*d*]imidazol-2-yl)-3,5-

dimethylphenyl)-2,2-dimethylpropanoic acid (compound 9) or a pharmaceutically acceptable salt or ester thereof.

10. The DGAT1 inhibitor for use according to any one of claims 5 to 7, wherein the DGAT1 inhibitor is an antibody.

11. The DGAT1 inhibitor for use according to any one of claims 5 to 10, wherein the use is for treatment of a human.